Latest News Archive

Please select Category, Year, and then Month to display items

UFS Student Publishes Book on Love and Life in the African Context

12 April 2022 | Story Anthony Mthembu | Photo Supplied

“The reason I write is because I know that there will be a time when people such as my grandmother and her peers will not be around to tell us stories by word of mouth, hence we need to preserve the stories they tell us in black and white,” said Siphilangenkosi Dlamini.

The fourth-year Governance and Political Transformation student at the University of the Free State (UFS) is the author of a book, titled Magic and Other Authentic Experiences. The book is a compilation of 13 short stories that follow the lives of a vast pool of characters as they experience chaos, love, and tragedy, among other things.

Some of the stories highlighted in the book

The chapter ‘The House on Marloth Street’ delineates the story of a young woman named Gracious, who is forced into prostitution to earn her keep by an elder in her life. The book also sheds light on the intricacies of young love through a story titled ‘The Suicide Note’. This story follows the lives of two characters named Menzi and Lulu, whose lives reach a devastating end because of secrets, deceit, and forbidden love. However, one of Dlamini’s favourite stories in the book is titled ‘Girl on the Bus’, which is based on a real-life occurrence. “It was one of those rare experiences where you meet someone and they are full of life,” he stated.

The book is ultimately a manifestation of Dlamini’s love of literature. In fact, he argues that “these stories are a portrayal of different experiences of young people stepping into the world and trying to navigate life, love, and relationships”. This can be seen in the first story in the book, titled ‘Magic on Campus’, which is an account of Dlamini trying to pursue a young woman he met on campus, and highlighting how she made him feel.

Making strides through literature

Dlamini’s authentic storytelling led to three of his stories being selected as part of the curriculum for the English Academic Literature module, which is included in most faculties at the UFS. As many of the students at the UFS are exposed to this work, he states that, “I would love this book to symbolise the importance of telling African stories”. Although Dlamini is making strides with this book, he is still working on expanding the book’s reach. “I’m emailing bookstores every day, trying to get the book into bookstores,” he said.

Future endeavours for the young author

As someone who strongly believes in the preservation of African literature and the portrayal of African love stories in their most authentic context, Dlamini is currently working on his next project. The project would count as his first novel and is a sequel to the stories from Magic and Other Authentic Experiences. In this novel, Dlamini explores a world in which the various characters are placed in a similar setting, and the experiences they would have if their lives were to intersect.

The book is currently available for purchasing at R100 per copy. Those interested in purchasing a copy may contact Siphilangenkosi Dlamini on +27 84 374 0032 or 2018245304@ufs4life.ac.za.

Magic and Other Authentic Experiences book cover

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept